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The secretory pathway is a process characteristic of cells specialized in secretion such as 
endocrine cells and neurons. It consists of different stages that are dependent on specific 
transport of proteins in vesicular-tubular carriers. Biochemical analyses have unveiled a number 
of protein families that confer identity to carrier vesicles and specificity to their transport. 
Among them is the family of Rab proteins, Ras-like small GTPases that anchor to the surface 
of transport vesicles and participate in vesicle formation from the donor compartment, 
transport along cytoskeletal tracks, and docking and fusion with the acceptor compartment. 
All of these functions are accomplished through the recruitment of effector proteins, such 
as sorting adaptors, tethering factors, kinases, phosphatases, and motors. The numerous 
Rab proteins have distinct subcellular distributions throughout the endomembrane system, 
which ensures efficient cargo transfer. Rab proteins act as molecular switches that alternate 
between a cytosolic GDP-bound, inactive form and a membrane-associated GTP-bound, active 
conformation. Cycling between inactive and active states is a highly regulated process that 
enables Rabs to confer spatio-temporal precision to the different stages through which a vesicle 
passes during its lifespan. This review focuses on our current knowledge on Rab functioning, 
from their structural features to the multiple regulatory proteins and effectors that control Rab 
activity and translate Rab function. Furthermore, we also summarize the information available 
on a particular Rab protein, Rab18, which has been linked to the control of secretory granule 
traffic in neuroendocrine cells.
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they undergo extensive sorting. From there, endocytosed molecules 
can then be recycled to the plasma membrane, transported to the 
trans-Golgi network, or addressed to lysosomes via late endosomes 
for  degradation (Seaman, 2008).
Shuttle vesicles mediate most of the transfer of proteins between 
the different compartments of the secretory pathway. This process 
comprises several sequential steps: first of all, coat complexes are 
responsible for both, the formation of transport vesicles, which 
occurs by budding and fission from the donor compartment, and 
the specific incorporation of cargo into the newly formed vesicles 
(Brett and Traub, 2006). After uncoating, vesicles move to the 
acceptor compartment, normally by means of their association 
with motor proteins that interact with and move along cytoskeletal 
tracks (Brett and Traub, 2006). In the proximity of the target com-
partment, vesicles are transiently linked to the acceptor membrane 
by a multifactorial complex in a process referred to as tethering. 
Finally, vesicles dock and fuse with the acceptor membrane allowing 
cargo unload to the acceptor compartment. A plethora of proteins 
that ensure the specificity and efficiency of cargo selection, vesi-
cle targeting, and fusion, control tightly each one of these stages. 
These proteins include tethering factors, v-SNARE and t-SNARE 
complexes, and Rab GTPase proteins (Figure 1; Bonifacino and 
Glick, 2004; Jahn and Scheller, 2006; Takamori et al., 2006). This 
review focuses on the latter group of proteins. First, it provides 
a general picture on the  common  molecular characteristics and 
The secretory pathway is an intricate, multi-step process that 
comprises the sequential participation of numerous subcellular 
mechanisms, such as synthesis, modification, sorting, and deliv-
ery of proteins that are secreted to the extracellular milieu or that 
are components of a variety of intracellular membrane compart-
ments and the cell surface (Bonifacino and Glick, 2004). Proteins 
transported along the secretory pathway are synthesized by ribos-
omes associated to the ER-membrane and are translocated into 
the lumen of this organelle. Then, proteins are packed into vesi-
cles and transferred to the Golgi complex passing through the ER/
Golgi intermediate compartment (i.e., ERGIC). At the more distal 
region of this organelle, the trans-Golgi network, proteins are sorted 
into different types of vesicles according to their final destinations 
(Gerdes, 2008). Some proteins traffic to the constitutive secretory 
pathway, which is common to all cell types and responsible for 
the continuous delivery of protein and lipid components to the 
plasma membrane and extracellular matrix. The regulated secre-
tory pathway is a landmark of specialized secretory cells, such as 
endocrine cells and neurons, that form and store secretory vesicles 
containing specific secretory cargoes to be exocytosed in a regu-
lated manner upon cell surface receptor stimulation (Park and Loh, 
2008). The trans-Golgi network is also the intracellular compart-
ment wherein the secretory and endocytic pathways converge. In 
the latter pathway, molecules are internalized from the cell surface 
in endocytic vesicles and transported to early endosomes, wherein 
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Hammer III and Wu, 2002; Kuroda and Fukuda, 2005). Finally, 
Rab GTPases also participate in vesicle tethering, docking, and 
fusion events. They associate with v-SNARE and/or t-SNARE pro-
teins forming trans-SNARE complexes, thus organizing fusion-
competent microdomains in the acceptor membrane (Wickner 
and Schekman, 2008). Figure 1 illustrates the involvement of Rab 
proteins in the different steps of the life cycle of carrier vesicles 
from vesicle formation to fusion.
Besides direct functions in vesicle dynamics, Rab proteins also 
serve as intermediates in the integration of extracellular signals into 
the molecular machinery accountable for intracellular membrane 
traffic (Miaczynska et al., 2004). They act as regulated molecular 
switches, cycling between an inactive, GDP-bound cytosolic state 
and an active, GTP-bound membrane associate state (Pfeffer and 
Aivazian, 2004; Seabra and Wasmeier, 2004; Pfeffer, 2005). Thus, 
the control of this activity cycle, which is dependent on a wide 
spectrum of signal transduction-related proteins, is key to confer-
ring spatial and temporal coordination to the cellular response. 
Altogether, this array of functions has led to the widely accepted 
view that Rab proteins are core constituents needed for orches-
trating the intracellular organization of endomembrane systems. 
Consequently, dysfunctions affecting synthesis and/or activity of 
these proteins entail the appearance of an important number of 
severe human diseases (Zerial and McBride, 2001).
mechanisms of action of Rab GTPases in relation to the secretory 
pathway. Then, it discusses the information available on a par-
ticular member of this family of proteins that regulates secretory 
granule traffic in neuroendocrine cells, Rab18 (Vazquez-Martinez 
et al., 2007).
The Rab GTPase family
Monomeric Rab proteins, members of the Ras superfamily of small 
GTPases, control multitude of vital cellular processes including 
protein exocytosis and endocytosis, intracellular signaling, differ-
entiation, and development. These general functions are accom-
plished via regulation of intracellular vesicle dynamics, from their 
formation to their fusion with the correct target membrane. Rab 
proteins control vesicle genesis from donor compartments by 
forming part of the so-called multi-subunit Rab tethers, which 
are regulatory complexes that interact with coat proteins, such 
as COPI, COPII, and clathrin, influencing their recruitment to 
vesicle budding zones and, ultimately, defining the newly formed 
vesicle identity (Angers and Merz, 2010). Rab proteins also deter-
mine the specificity of carrier-vesicle addressing and transport to 
acceptor compartments by interacting directly or indirectly with 
molecular motors, recruiting them to the surface of transport 
vesicles and even acting as modulators of the motor processivity 
along cytoskeletal tracks (Echard et al., 1998; Jordens et al., 2001; 
FiguRE 1 | Different stages of vesicle budding from the donor compartment 
and fusion with the acceptor compartment. (1) Vesicle formation and initiation 
of coat and adaptor proteins assembly. Specific Rab proteins interact with 
tethering factors anchored to the donor membrane to form multi-subunit Rab 
tethers that address coat proteins such as COPI, COPII and clathrin, and adaptor 
proteins that determine the specificity of cargo to the surface of the budding 
vesicle. (2) Uncoating and specific transport of carrier vesicles along cytoskeletal 
tracks. Newly formed vesicles lose their coat by inactivation of particular Rab 
GTPases and activation of uncoating enzymes. Motor protein complexes 
recognize and recruit uncoated vesicles to cytoskeletal tracks to transport the 
cargo to the corresponding acceptor compartment. These motor protein 
complexes include Rab proteins that modulate the processivity and direction of 
the motor protein movement. During transport, specific v-SNARE complexes are 
added to the surface of vesicles, thus conferring specificity to their fusion with 
the corresponding target compartment. (3) Tethering of vesicles to the acceptor 
compartment. Vesicles in the proximity of the target compartment become 
tethered to its membrane in a process driven by a Rab protein/tether factor 
complex. (4) Docking of vesicles to the acceptor compartment. v-SNARE and 
t-SNAREs assemble into a four-helix bundle and vesicles are approached to the 
target membrane. (5) Membrane fusion and release of cargo into the target 
compartment. Trans-SNARE complexes promote fusion of the vesicle and 
acceptor lipid bilayers. Cargo is transferred to the acceptor compartment, and the 
SNAREs are recycled. Rab proteins are inactivated and released into the cytosol, 
wherein they remain until a new cycle of activation is initiated.
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Rab2/Rab7 chimera proteins to the early or late endosomal 
 compartments, respectively (Chavrier et al., 1991). However, sub-
sequent studies suggested that the membrane targeting of Rab 
proteins is more complex, involving non-hypervariable domain 
determinants as well (Stenmark et al., 1994; Ali et al., 2004). The 
particular signatures of the Rab C-terminal domain comprise CC, 
CXC (i.e., Rab-CXC proteins), or CAAX motifs (i.e., Rab-CAAX 
proteins), where C is cysteine, A is usually an aliphatic residue, 
and X is any amino acid. Rab-CXC proteins, the most abundant 
group, undergo posttranslational modification by covalent addi-
tion of two geranylgeranyl (20-carbon) isoprenoids onto the 
C-terminal cysteines, which is necessary for these Rabs to associ-
ate with cellular membranes to carry out intracellular functions 
(Lane and Beese, 2006; Leung et al., 2006). This enzymatic reaction 
is catalyzed by geranylgeranyltransferase type II (i.e., RGGT; also 
known as RabRGGT) but only when Rab proteins are in complex 
with an accessory protein known as Rab escort protein (i.e., REP; 
Farnsworth et al., 1994). Two possible mechanisms for Rab prenyla-
tion have been proposed. The first suggests that newly translated 
Rabs bind REP and, then, the complex is recognized by RGGT. After 
addition of the geranylgeranyl moieties to the cysteine residues, 
RGGT dissociates from REP, which remains bound to the Rab pro-
tein and delivers it to target membranes to be, finally, released into 
the cytosol for a new prenylation cycle. In the alternative hypoth-
esis, RGGT and REP would already form a complex prior to bind-
ing Rab proteins. After prenylation, RGGT dissociates from REP/
Rab, and REP escorts the prenylated Rab to membranes (Andres 
et al., 1993; Alexandrov et al., 1994; Thoma et al., 2001a,b). In the 
case of Rab-CAAX proteins, which are the less represented group 
of Rab proteins (e.g., Rab8, Rab13, Rab18, Rab23, and Rab38), 
after protein translation only one geranylgeranyl group is added 
to the C-terminal domain by RGGT in the presence of REP. Then, 
mono-geranylgeranylated Rabs need further processing to be re-
directed to their target membranes, which involves addition of a 
carboxyl–methyl group in the prenylated cysteine by sequential 
action of two methyltransferases located in the ER-membrane 
(Leung et al., 2007). Although di-geranylgeranylated Rab-CXC 
proteins also require methylation for correct membrane targeting, 
only one methyltransferase is involved in catalyzing this reaction 
(Leung et al., 2007).
As mentioned earlier, activation of Rab GTPases by exchange of 
GDP for GTP entails major conformational changes in the tertiary 
structure of the protein that define the specificity of Rabs. This 
reaction is catalyzed by guanine nucleotide exchange factors (i.e., 
GEFs), which weaken GDP interaction with the switch regions and 
facilitate GDP release and the subsequent GTP binding (Vetter 
and Wittinghofer, 2001). The large number of GTPases requires 
a multitude of GEFs to ensure signaling specificity. GEF proteins 
characterized so far share distinctive hallmarks in their sequences, 
such as Vsp9- Sec2- or Mss4-like domains (Yu and Schreiber, 1995; 
Delprato et al., 2004; Mizuno-Yamasaki et al., 2010). Regarding the 
mechanisms of action whereby GEFs facilitate GDP/GTP exchange, 
although different proteins use diverse strategies, in all cases, GEF 
interaction with the Rab protein perturbs the molecular conforma-
tion of switches I and II. This sterically occludes the Mg2+-binding 
site essential for the high-affinity binding of the GDP. The high 
GTP/GDP ratio present in the cytosol allows rapid binding of 
A number of genome analyses have revealed that in the yeast 
Saccharomyces cerevisiae Rab family is composed of 11 members, 
but that in humans there are almost 70 different Rab proteins (Zerial 
and McBride, 2001; Colicelli, 2004). The fact that there exist almost 
seven times more members in mammals than in yeasts has been 
attributed to the necessity of fulfilling the specificity demands of an 
endomembrane-trafficking system highly increased in complexity 
during evolution (Dacks and Field, 2004, 2007). Thus, different 
Rab GTPases localize to distinct subcompartments and, although 
in some instances several Rabs may associate to the same organelle, 
they always segregate in specific spatio-temporal microdomains 
(Sonnichsen et al., 2000). The complexity of the Rab protein system 
increases enormously when considering their mode of action. Rab 
GTPases always act in conjunction with an ample range of different 
proteins that either regulate Rab activity or are regulated by Rab 
activation. Proteins comprising the latter group, the so-called Rab 
effector proteins, are the ultimate responsible for translating Rab 
function into the molecular machinery that drives intracellular 
vesicle positioning (Stenmark, 2009).
STRucTuRal and funcTional feaTuReS of Rab PRoTeinS
To date, crystal structures are available for at least 16 Rab GTPases 
in the GTP-bound conformation and 17 in the GDP-bound one, 
which has allowed some generalization about the structural organ-
ization of Rab proteins (Eathiraj et al., 2005; Lee et al., 2009). 
The tertiary structure of this group of proteins is very similar 
to the structural folding of other GTPases of the Ras family. It 
consists of a central barrel composed of six β-sheets surrounded 
by five α-helices. In α1 resides a region broadly conserved among 
all GTPases (Ostermeier and Brunger, 1999), which includes the 
GTP-binding platform and the element for binding Mg2+, a cofac-
tor required for high-affinity nucleotide binding and hydrolysis 
(Vetter and Wittinghofer, 2001). Further structural analysis of 
Rab proteins has defined two regions, termed switches I and II, 
which are located between α1/β2 loop and β3/β4 loop, respectively. 
These regions are critical for conferring functional specificity to 
Rabs, as they contact the γ-phosphate of GTP and, together with 
the interswitch region, exhibit large conformational differences 
between the inactive and active states (Dumas et al., 1999; Stroupe 
and Brunger, 2000). Similarities and dissimilarities in the tertiary 
structure adopted by these regions have led to classification of the 
Rab family into eight phylogenetic groups composed of clusters 
of related Rabs with similar active conformations (Pereira-Leal 
and Seabra, 2001). For example, in Rab5 and Rab22, which both 
belong to subfamily V, switches I and II adopt nearly identical 
active conformations (Eathiraj et al., 2005).
The region exhibiting highest evolutionary divergence in terms 
of amino acid sequence of Rab proteins constitutes the C-terminal 
domain, the so-called hypervariable domain. Hypervariable 
domains have been proposed to be responsible for Rab protein 
localization (Chavrier et al., 1991). This was first supported by 
subcellular fractionation studies using a hybrid protein consisting 
of 166 N-terminal residues of Rab2, which localizes to the ERGIC, 
fused with either the 35 C-terminal amino acids of Rab5, a protein 
that targets the early endosomal compartment, or the 35 C-terminal 
amino acids of Rab7, which specifically binds to late endosomes. 
These substitutions were sufficient to address Rab2/Rab5 and 
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PRoTein STRucTuRe, SubcellulaR localizaTion and 
funcTion of Rab18
Rab18 was initially cloned from mouse pituitary AtT20 cells in 
the context of a PCR-based strategy aimed at cloning members of 
the Rab family from rodent pituitary (Yu et al., 1993). The cDNA 
sequence isolated coded for a 23.5-kDa protein with a consensus 
GTP-binding domain and sequence motifs that are characteristic of 
the Rab family of proteins (Yu et al., 1993). Northern blot analysis 
showed that Rab18 is ubiquitously expressed, but expression is 
higher in neuroendocrine tissues, including brain and pituitary 
(Yu et al., 1993). In 2005, Kukimoto-Niino and coworkers released 
the first X-ray diffraction crystal of human Rab18 (DOI: 10.2210/
pdb1x3s/pdb), which confirmed the high structural homology of 
Rab18 with other members of the Rab family.
The hypervariable C-terminal domain of Rab18 contains a CAAX 
amino acid motif, which supports that this GTPase is monopre-
nylated by RGGT in the presence of a REP (likely REP-1). It has been 
shown that, after prenylation, Rab18 is post-translationally modi-
fied by incorporation of carboxyl–methyl groups in its C-terminal 
domain, a reaction that takes place in specialized subdomains of 
the ER-membrane enriched in the methyltransferases Icmt and 
Rce1 (Leung et al., 2007). After methylation, Rab18 is released into 
the cytosol and it can begin cycling between its inactive, cytosolic 
GDP-bound conformation and its active membrane-associated, 
GTP-bound form. By analogy with data from other members of the 
Rab family, it seems conceivable that this GDP-to-GTP cycle could 
also be regulated in the case of Rab18 by specific GEFs, GTPase 
activator proteins (i.e., GAPs), guanine dissociation inhibitors (i.e., 
GDIs) and GDI displacement factors (i.e., GDFs), although none 
of these proteins have been identified so far.
Regarding the intracellular localization of Rab18, pioneering 
confocal and electron microscopy studies by Lutcke et al. (1994) in 
kidney and intestinal epithelial cells showed that Rab18 immunola-
beling is predominantly localized to vesicular-tubular structures 
below the apical brush border of proximal tubule cells. Given that 
these structures closely resemble the dense apical tubules implicated 
in membrane recycling to the apical surface and in transcytosis, 
the authors suggested that Rab18 might play a role in endosome 
recycling. However, a subsequent study aimed at elucidating how 
Salmonella escapes transport to lysosomes during endocytosis in 
macrophages showed that the bacteria bypasses the endocytic route 
by accumulating in a specialized compartment enriched in Rab18 
but lacking early or late endosomal markers, such as transferrin and 
Rab7, respectively (Hashim et al., 2000). Later studies carried out 
in adipocytes, fibroblasts and neuroendocrine cells have also failed 
to localize Rab18 to early or late endosomes (Martin et al., 2005; 
Ozeki et al., 2005; Vazquez-Martinez et al., 2007; Dejgaard et al., 
2008). Instead, Rab18 immunoreactivity colocalized with specific 
markers of lipid droplets in 3T3-L1 adipocytes (Martin et al., 2005; 
Ozeki et al., 2005), secretory granules in PC12, AtT20, and melano-
trope cells (Vazquez-Martinez et al., 2007) and cis-Golgi and ER 
compartments in NRK, Vero, and COS7 fibroblasts (Dejgaard 
et al., 2008). Together, these results indicate that the subcellular 
distribution of Rab18 depends strongly on the cell type considered 
and this, in turn, suggests that this GTPase may subserve distinct, 
specific roles depending on cell specialization and its interaction 
with  different effectors.
GTP and the subsequent activation and translocation of the Rab 
 protein to the corresponding target compartment. Activity of GEF 
proteins is strictly regulated by protein–protein and protein–lipid 
interactions, binding of second messengers and posttranslational 
modifications, which are thus key control points of the Rab-driven 
spatio-temporal coordination of endomembrane transport. Among 
a long list of Rab GEFs, we can cite as examples Mon1 that has been 
shown to act as GEF of Rab7 and its yeast homolog Ypt7 after acti-
vation by Ccz1 (Nordmann et al., 2010), TRAPP-I that promotes 
activation of Ypt1p in yeast and Rab1 in mammalian cells at the 
surface of ER-Golgi transport vesicles (Sacher et al., 2008), Sec2p 
that acts as sequential GEF for the yeast Rabs Ypt32p and Sec4p in 
the early stages of the secretory pathway (Mizuno-Yamasaki et al., 
2010), and Rabex-5 that activates Rab5 in early endosomes, which 
is necessary for membrane fusion (Delprato et al., 2004).
Although Rab proteins are considered GTPases, their capacity 
to hydrolyze GTP is in fact very low and, thereby, they require help 
from a group of proteins referred to as GTPase-activating proteins 
(i.e., GAPs) to accelerate and to make this process efficient. GAPs 
belong to a very heterogeneous protein family whose members 
only share a common TBC1 domain, although the Rab substrate 
specificity of GAPs does not appear to reside in this sequence (Barr 
and Lambright, 2010). Rather, GAPs have been proposed to bind 
particular Rabs either due to their specific location or to spatial-
dependent interactions with regulatory proteins. For example, 
TBC1D20 is an ER-membrane protein and, consequently, it is only 
able to target Rab proteins that share this location (Haas et al., 
2007). On the other hand, Gyp7p only acts on the yeast Rab Ypt7p 
in concert with a protein kinase (Brett et al., 2008). As GEFs, GAPs 
are also highly regulated proteins. Their activity is also tightly con-
trolled by interaction with many regulatory proteins and lipids, by 
second messengers and by posttranslational modifications, which 
highlights the importance of these proteins in the coordination of 
the Rab-driven cellular responses (Barr and Lambright, 2010).
Finally, other proteins also play important roles in modulating 
Rab activity, the so-called Rab GDP dissociation inhibitor (i.e., 
GDI) and GDI displacement factor (i.e., GDF). Whereas GDI pre-
vents GDP release, thereby stabilizing the Rab protein in its inac-
tive form (Pfeffer and Aivazian, 2004), GDF recognizes specific 
Rab–GDI complexes and promote GDI release and the subsequent 
binding of a GEF to the Rab protein (Pfeffer and Aivazian, 2004). 
Regarding GDI, there exist two isoforms in human cells: GDIα, 
whose expression is restricted to brain tissue, and the ubiquitously 
expressed GDIβ (Alory and Balch, 2001). RabGDI and REP mol-
ecules have regions of high sequence homology, and partially shared 
properties: they both bind inactive Rabs but, whereas RabGDI 
show very high-affinity for prenylated, GDP-bound Rabs, REP 
only interacts with unprenylated Rabs (Goody et al., 2005). On 
the other hand, the first GDF identified was the yeast protein Yip1, 
which interacts with the Rab proteins Ypt1 and Ypt31 (Yang et al., 
1998). In later studies, other members of the Yip protein family 
have been discovered. All of them are transmembrane proteins that 
present the C- and N-terminal domains facing the cytosol (Calero 
and Collins, 2002; Calero et al., 2002). A gene database survey has 
identified 16 putative Yips in humans, which supports the fact that 
each Yip protein can interact with numerous Rab proteins (Pfeffer 
and Aivazian, 2004).
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these findings were consistent with the idea that  interaction of 
Rab18 with secretory granules may function as a brake of granule 
traffic to control the amount of product released upon reception of 
a stimulatory input. Indeed, time-lapse video microscopy experi-
ments supported this view, as they demonstrated that the motility 
of vesicles bearing Rab18 is reduced as compared with the averaged 
movement of the granule population. Thus, in cells overexpress-
ing the secretory neuropeptide NPY fused to GFP, the majority 
of NPY-containing secretory granules displayed long and directed 
trajectories, whereas in Rab18-overexpressing cells, most gran-
ules bearing the GTPase exhibited short and confined trajectories 
(Vazquez-Martinez et al., 2007). This suggests that the presence of 
Rab18 in the surface of secretory granule impairs secretory granule 
transport. Rab18 could accomplish this function by modulating the 
activity of motor proteins either by direct interaction or indirectly 
by forming protein complexes with yet unknown effectors that 
would ultimately determine the processivity of motor proteins. In 
support of this, other members of the Rab family of GTPases have 
been reported to affect the secretory pathway in such a way. For 
example, Rab6 has been shown to associate with the microtubule 
motor Rabkinesin-6, thus promoting the delivery of vesicles from 
the Golgi to the ER (Echard et al., 1998), Rab4A interacts with 
dynein light chain and modulates its activity (Bielli et al., 2001), and 
Rab27A binds to the effector protein melanophilin, which links this 
GTPase to the actin motor myosin-Va and promotes melanosome 
secretion (Fukuda et al., 2002b).
To date, other Rab proteins, including Rab27A, Rab3A, and 
Rab11, have been reported to modulate Ca2+-triggered exocyto-
sis in neuroendocrine cells by interacting directly with secretory 
granules. Specifically, Rab27A promotes stimulated secretion 
in PC12 cells (Fukuda et al., 2002a), whereas Rab3A (Fischer 
von Mollard et al., 1991; Johannes et al., 1994, 1998) and Rab11 
(Khvotchev et al., 2003) have been shown to negatively regulate 
secretion in neurons. Rab3A has also been reported to decrease 
secretory granule release in pancreatic β-cells (Regazzi et al., 
1996) and adrenal chromaffin cells (Holz et al., 1994). However, 
although Rab3A and Rab18 are coexpressed in (neuro)endocrine 
cells and appear to display similar functions restraining secre-
tory granule release, as mentioned above, they do not coexist 
on the surface of the same secretory granule population, which 
supports the view that these two GTPases act at different steps 
of the secretory process. Rab3A has been found to be associated 
with secretory granules that are in close apposition to the plasma 
membrane, suggesting a role for this GTPase in the final steps of 
granule exocytosis (i.e., docking and fusion; Martelli et al., 2000; 
Schluter et al., 2004). Yet, ultrastructural analysis of the secre-
tory granules immunolabeled with Rab18 revealed that they are 
located at a distance from the plasma membrane that is unlikely 
to correspond to secretory granules in the docking stage, which 
suggests that Rab18 acts at earlier steps of the secretory process 
(Vazquez-Martinez et al., 2007). However, to date the molecular 
mechanism whereby Rab18 negatively modulates secretory gran-
ule transport and, therefore, granule release remains to be eluci-
dated. Future studies aimed at characterizing the Rab18 effector 
proteins and their relationship to the vesicle transport machinery 
will be necessary in order to obtain insight into the function of 
Rab18 in relation to the  regulated secretory pathway.
In relation to the participation of Rab18 in the secretory 
 pathway, a differential display analysis of genes expressed in pitui-
tary melanotropes enabled us to isolate the RAB18 gene by virtue 
of its preferential expression in a subset of cells exhibiting low 
hormone secretory activity (Malagon et al., 2005). Further subcel-
lular localization studies of Rab18 in (neuro)endocrine cells lines, 
such as the rat pheochromocytoma PC12 cell line, the adrenocor-
ticotropin (ACTH)-secreting AtT20 cell line, and α-melanotropin 
stimulating hormone-producing melanotrope cells showed that 
this GTPase mainly distributed diffuse in the cytosol under non-
stimulated conditions, whereas after specific stimulation of the cell 
secretory activity it colocalized with the secretory granule mark-
ers secretogranin II, chromogranin A, and NPY. However, Rab18 
did not colocalize with another member of the Rab family known 
to associate with secretory vesicles in their docking stage, Rab3A 
(Fischer von Mollard et al., 1991; Holz et al., 1994; Johannes et al., 
1994, 1998; Regazzi et al., 1996; Martelli et al., 2000; Schluter et al., 
2004). These findings suggested that in neuroendocrine cells Rab18 
cycles between the cytosol and the surface of a discrete population 
of secretory granules upon activation of the regulated secretory 
pathway (Vazquez-Martinez et al., 2007). This was confirmed by 
investigating the intracellular distribution of Rab18 mutants. We 
engineered two Rab18 mutants by substitution of specific amino 
acid residues in the GTP-binding platform and tagged them with 
GFP: one, Rab18(S22N), is deficient in GTP binding and, therefore, 
constitutively inactive, and the second, Rab18(Q67L), is unable 
to hydrolyze GTP even with help from GAPs and, therefore, con-
stitutively active. Transfection experiments carried out in PC12 
and AtT20 cells demonstrated that whereas the constitutively 
active mutant Rab18(Q67L) was always found in association with 
secretory granules under basal and stimulated conditions, the 
constitutively inactive mutant Rab18(S22N) remained cytosolic 
even after stimulation of hormone secretion (Vazquez-Martinez 
et al., 2007). In sum, as for other Rab proteins, replacement of 
GDP by GTP is also required for Rab18 to be translocated to its 
target compartment.
An important functional insight into the specific role of Rab18 
in (neuro)endocrine cells came from the observation that Rab18 
translocation to secretory granules was accompanied by a reduc-
tion in the secretory response of cells to stimulatory challenges. 
Specifically, when wild-type Rab18 protein or the constitutively 
active mutant was overexpressed in PC12 cells, secretion in response 
to a depolarizing pulse of K+ was significantly lower than in control 
cells (Vazquez-Martinez et al., 2007). Thus, HPLC quantification of 
the amount of dopamine released into the medium revealed that 
Rab18-overexpressing PC12 cells secreted less dopamine than non-
transfected cells or cells transfected with a control plasmid. This 
inhibitory effect was also observed at single-cell level by using a 
fluorescent styryl dye (i.e., FM5-95) that is endocytosed by the cells 
after each exocytotic event, the amount of internalized fluorophore 
being proportional to the number of secretory granules fused during 
the exocytotic event (Cochilla et al., 1999; Brumback et al., 2004). 
In the case of ACTH-secreting AtT20 cells, the inhibitory effect of 
Rab18 overexpression on the secretory rate was also observed in 
cells treated with the hypothalamic secretagog CRH at the popula-
tion level, quantifying ACTH release by ELISA, and at single-cell 
level, using FM5-95 (Vazquez-Martinez et al., 2007). Altogether, 
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Regarding Rab18, to date a number of microarray analyses have 
shown that RAB18 gene expression is deregulated in neuroendo-
crine gastrointestinal tumors (Hofsli et al., 2005), prostate adeno-
carcinoma (True et al., 2006), breast cancer (Yan et al., 2008), and 
pancreatic adenocarcinoma (Kalinina et al., 2010). These findings 
suggest that Rab18 may constitute a valuable target as a diagnos-
tic, prognostic, and/or therapeutic tool for these types of cancers. 
However, these studies do not provide further characterization of 
the precise relationship of this GTPase with the pathophysiology 
of these tumors. As mentioned before, we have demonstrated that 
Rab18 negatively modulate the secretory activity of neuroendo-
crine cells. Therefore, one could envisage that alterations in Rab18 
expression and/or activity would yield malfunctions of the secre-
tory process, such as those exhibited by many endocrine disorders 
characterized by hypersecretion of a particular hormone. This is 
the case for acromegaly, a pituitary tumor associated to high cir-
culating levels of growth hormone (GH; Melmed et al., 2002). We 
recently demonstrated that in patients with acromegaly elevated 
GH plasma levels arise from both somatotrope hyperplasia and 
altered secretory activity of individual cells (Vazquez-Martinez 
et al., 2008). These findings suggested that the pathological altera-
tions leading to GH hypersecretion might also have a secretory 
pathway-related molecular component intrinsic to each individual 
somatotropinoma cell. In fact, all acromegalic tissues analyzed 
exhibited an abnormally reduced level of Rab18 expression as 
compared to healthy pituitary glands or glands from patients with 
non-functioning adenomas that presented normal GH circulating 
levels. These findings pointed to the lack of this protein as one of 
the possible causatives of the hypersecretory activity of somatotro-
pinoma cells. Interestingly, double immunoelectron microscopy 
revealed that the proportion of Rab18-immunolabeled secretory 
granules was consistently lower in somatotropes from acromegalic 
patients than in those from patients with non-functioning adeno-
mas. Accordingly, Rab18 protein content observed by immunofluo-
rescence was also lower in single pituitary cells from the former 
patients. Furthermore, the hypersecretory activity shown by these 
somatotropinoma cells could be reverted substantially by overex-
pression of Rab18, thereby suggesting that modulation of Rab18 
production may represent an important point of control within 
the process of hormone secretion in these tumor cells. Altogether, 
these results suggest that low Rab18 content in somatotropinoma 
cells could result in the partial loss of control on the molecular 
mechanism that retains a particular subset of the secretory granules 
from being released under basal conditions and/or on stimulatory 
inputs. Figure 2 presents a theoretical model of the contribution 
of Rab18 to the hypersecretory state of somatotropinoma cells in 
acromegaly. Finally, it is worth to highlight that these data are the 
first report directly linking a member of the Rab GTPase family 
with dysfunctions of endocrine cells in humans.
concluSion
In the last two decades a large contribution to ascertain the specific 
participation of each Rab protein in the endomembrane organiza-
tion and the secretory process has been made. Nevertheless, when 
taking into account the diversity of Rabs in humans and the high 
number of Rab regulators and effectors, it is evident that there is 
still a long way until we get a unifying view to better understand 
Rabs in human diSeaSe
Alterations in Rab proteins and their associated proteins or 
 effectors are being increasingly implicated in human disease. 
Griscelli syndrome type 1 was the first human disease discovered 
to be directly related to a Rab protein, namely a loss-of-function 
mutation in a Rab protein, Rab27A (Menasche et al., 2000). This 
disease is a rare, autosomal recessive disorder that results in pig-
mentary dilution of the skin and the hair, due to the accumula-
tion of melanosomes in melanocytes, and different degrees of 
immunodeficiency, due to uncontrolled T-cell and macrophage 
activation (Menasche et al., 2000). Another type of Griscelli syn-
drome, GS type 2, is due to a mutation in the Rab27A effector 
and motor protein myosin-Va. These patients exhibit primary 
neurological defects but, unlike patients with GS type 1, normal 
immune function (Menasche et al., 2000). Charcot–Marie–Tooth 
type 2B neuropathy represents a further Rab-related human dis-
ease. This is an autosomal dominant axonal disease characterized 
by sensory loss, distal muscle weakness and frequent infections in 
feet and toes (Young and Suter, 2003). Four different mutations 
in RAB7 gene have been identified as causative of this disease. 
All of them give rise to constitutively active mutants unable to 
hydrolyze GTP that have been proposed to alter the retrograde 
axonal transport and, in particular, neurotrophin trafficking and 
signaling (Cogli et al., 2009).
Mutations in Rab regulatory proteins also affect the activity 
of Rabs and, as a consequence, have profound effects on the cell 
functioning. For instance, loss-of-function mutations in REP-1 
that lead to choroideremia, an X-linked form of retinal degen-
eration characterized by an excess of unprenylated Rab27A in 
retinal pigment epithelial cells (Seabra, 1996). Furthermore, a 
mutation in RabGDIa has been related to X-linked non-specific 
mental retardation (D’Adamo et al., 1998). This mutant leads to 
a reduced Rab3A recycling in synapses and, therefore, impaired 
neurotransmitter release that profoundly affects development of 
the central nervous system (D’Adamo et al., 1998). RabGGT has 
also been linked to human disease. A mutation in the α-subunit 
has been proposed to cause Hermansky–Pudlak syndrome, which 
is a rare autosomal recessive disorder characterized by albinism, 
bleeding, and lysosomal lipofuscin accumulation (Huizing 
et al., 2000).
Altered expression of a number of Rab proteins is also associated 
with different types of cancer. For example, expression of Rab3 
is elevated in cancers of the nervous system and neuroendocrine 
cells (Culine et al., 1992), as well as insulinomas (Lankat-Buttgereit 
et al., 1994), Rab5 expression appears to be upregulated in rela-
tion to the degree of malignancy and metastasis of human lung 
adenocarcinoma (Li et al., 1999), while Rab20 levels in pancreatic 
carcinoma samples are abnormally enhanced (Amillet et al., 2006), 
etc. Rab25 is perhaps the Rab family member best known in terms 
of its involvement in cancer. Extreme levels of Rab25 transcripts 
have been found in diverse epithelial cancers, such as ovarian and 
breast cancers (Cheng et al., 2004; Agarwal et al., 2009). In addition, 
Rab25 expression in these tissues is positively correlated with cancer 
aggressiveness and progression. Physical interaction of Rab25 with 
the adhesion protein integrin has been reported and proposed as 
the driving force for increased tumor invasion (Cheng et al., 2004; 
Subramani and Alahari, 2010).
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FiguRE 2 | Theoretical model of the contribution of Rab18 to the 
hypersecretory state of somatotropinoma cells in acromegalic patients. 
In physiological conditions (left panel), somatotrope cells express normal 
levels of Rab18, which retains a number of GH-containing secretory granules 
from being released upon stimulatory inputs, thus ensuring the maintenance 
of the secretory response of cells within non-pathological limits. In 
acromegalic patients (right panel), somatotropinoma cells express lower 
levels of Rab18, which would cause uncontrolled secretory granule transport 
toward the plasma membrane and, consequently, an abnormally enhanced 
secretory response.
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